Autoimmune liver disease-related autoantibodies in patients with biliary atresia

Table 1 Demographic and clinical features, and biochemical parameters¹ of biliary atresia patients and non-biliary atresia controls n (%)

Variable	BA, n = 124	Non-BA, n = 140
		Other liver diseases2, n = 92	Healthy, n = 48
Age, mo	2.9 (1.9-3.0)	2.8 (2.0-3.2)	3.4 (2.0-4.0)
Sex, male/female	60/64	50/42	25/23
METAVIR score
F0	4 (3.2)	NA	NA
F1	37 (29.8)	NA	NA
F2	24 (19.4)	NA	NA
F3	50 (40.3)	NA	NA
F4	9 (7.3)	NA	NA
ALT, U/L	162.4 (104.3-204.6)a	132.0 (70.5-247.5)	28.1 (22.4-40.8)
AST, U/L	190.5 (151.4-257.4)a	195.9 (117.0-292.5)	38.0 (26.0-52.3)
γ-GT, U/L	716.0 (411.0-1142.5)a	598.4 (189.5-1043.2)	32.7 (23.4-46.3)
ALP, U/L	406.8 (316.5-522.2)a	517.0 (409.7-660.3)	275.8 (189.0-345.6)
TBIL, μmol/L	157.0 (126.5-184.0)a	145.7 (107.1-196.5)	6.5 (2.8-14.8)
DBIL, μmol/L	130.5 (103.5-152.7)a	110.1 (88.4-137.8)	3.1 (1.0-4.9)

Data are described as median (interquartile range: 25^th-75^th percentile). ¹Reference intervals: ALT, 3-35 U/L; AST, 5-60 U/L; γ-GT, 13-57 U/L; ALP, 118-390 U/L; TBIL, 2-17 μmol/L; DBIL, 0-7 μmol/L;

²Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls.

^aP < 0.05 vs healthy controls. ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BA: Biliary atresia; DBIL: Direct bilirubin; FO-F4: Fibrosis scores 0-4; γ-GT: Gamma-glutamyl transpeptidase; NA: Not applicable; TBIL: Total bilirubin.